Dubin-Johnson Syndrome Workup
- Author: Simon S Rabinowitz, MD, PhD, FAAP; Chief Editor: BS Anand, MD more...
The diagnosis of Dubin-Johnson syndrome (DJS) should be considered in all individuals with elevated conjugated bilirubin levels with otherwise normal liver function test findings. The diagnosis can be confirmed by demonstrating an increase in the ratio of urinary coproporphyrin I to coproporphyrin III.
A combination of intense and prolonged visualization of the liver following intravenous administration of the radiopharmaceutical dye, with delayed to no visualization of the gallbladder, is unique to Dubin-Johnson syndrome (DJS).
Laboratory studies reveal conjugated hyperbilirubinemia, with total bilirubin serum levels usually in the 2- to 5-mg/dL range (but potentially as high as 25 mg/dL).
Results of other laboratory tests, including liver enzymes, serum albumin, and hematologic studies (eg, complete blood count [CBC], reticulocyte count), tend to be within reference ranges. Urine dipstick analysis may reveal bilirubinuria.
Prothrombin time is usually within normal limits, but it can be prolonged in Iranian Jewish patients with associated factor VII deficiency.
Reduced prothrombin activity resulting from lower levels of clotting factor VII is observed in 60% of patients with Dubin-Johnson syndrome.
Because MRP2 also transports leukotrienes into the bile, patients with Dubin-Johnson syndrome have defective biliary secretion and increased urinary excretion of leukotriene metabolites. This may become a noninvasive diagnostic assay for this condition.
Coproporphyrins are byproducts of heme biosynthesis. Normally, coproporphyrin I is preferentially excreted in bile, whereas coproporphyrin III is preferentially excreted in urine.
The urinary excretion of coproporphyrin isomers, however, has a fairly unique pattern in patients with Dubin-Johnson syndrome and can be used as a pathognomonic feature of the condition when congenital erythropoietic porphyria and arsenic poisoning have been excluded.
An increase in the urinary excretion of coproporphyrin I and a decrease in the excretion of coproporphyrin III are observed in Dubin-Johnson syndrome. This results in total urinary coproporphyrin excretion (I+III) that is nearly normal when compared with unaffected individuals. The unique feature in Dubin-Johnson syndrome, however, is that 80% of the urinary coproporphyrin is type I in patients with Dubin-Johnson syndrome, compared with only 25% in in other persons. (Fecal coproporphyrin levels remain normal.)
In persons who are heterozygous for Dubin-Johnson syndrome, an intermediate ratio of urinary coproporphyrin I to coproporphyrin III is observed; these levels have been used to create family trees and to establish the recessive nature of the condition.
How a defect in an apical transporter creates this variance in urinary isomers remains unexplained, with several possible pathogenic mechanisms.
Interestingly, for the first 2 days of life, healthy neonates have ratios of urinary coproporphyrin similar to those seen in patients with Dubin-Johnson syndrome; by 10 days of life, however, these levels convert to the normal adult ratio.
Computed tomography (CT)–scan findings in patients with Dubin-Johnson syndrome reportedly show a significantly higher attenuation than that seen in control subjects. Ultrasonography reveals a normal biliary tree and, in the first image below, demonstrates acalculous cholecystitis. The second image, a radiograph, shows acute cholecystitis.
Patients with Dubin-Johnson syndrome tend to have unique findings on hepatobiliary scans. Specifically, the liver is visualized immediately following intravenous administration of the radiopharmaceutical dye and remains intensely and homogeneously visualized for up to 120 minutes.
The gallbladder may be visualized after a delay of up to 90 minutes after dye injection in some patients and may not be observed at all in others. (Normally, images of the gallbladder are observed within 30 minutes after dye injection.)
This combination of intense and prolonged visualization of the liver and delayed or failed visualization of the gallbladder is unique to Dubin-Johnson syndrome (DJS) in comparison with other primary liver abnormalities. These findings, however, can be mistaken for evidence of gallbladder disease if the patient presents with abdominal pain and may result in an unnecessary cholecystectomy.
Oral cholecystography fails to visualize the gallbladder in patients with Dubin-Johnson syndrome.
In general, procedures are not necessary to confirm the diagnosis of Dubin-Johnson syndrome. If a patient is suspected of having the disease, the diagnosis can be confirmed by the test for urinary coproporphyrins, as described earlier.
Although a liver biopsy is not necessary for the diagnosis of Dubin-Johnson syndrome, patients may be noted to have a dark liver during routine surgery (eg, cholecystectomy), prompting biopsy.
Deposition of melaninlike pigment occurs in the livers of patients with Dubin-Johnson syndrome but not in those with Rotor syndrome, a characteristic that helps to differentiate the 2 diseases. Macroscopically, the pigment can cause the liver to appear dark or almost black. (See the image below.)
Microscopically, there is accumulation of coarsely granular pigment, which is most pronounced in the centrilobular zones (see the image below). No associated scarring, hepatocellular necrosis, or distortion of zonal architecture is present. The amount of pigment can vary among patients and within an individual. Certain diseases (eg, viral hepatitis) can cause the pigment to disappear. The pigment reaccumulates slowly once the acute process is resolved. Electron spin resonance spectroscopy suggests that the pigment is composed of polymers of epinephrine metabolites.
The changes in the hepatocytes coexist with marked stimulation and enhanced phagocytic activity of Kupffer cells. This manifests in the accumulation of pigment deposits within their cytoplasm that corresponds to those observed in hepatocytes. Hyperactive pericentral Kupffer cells, which are involved in the response to pigmentary material originating from disintegrated hepatocytes, may play an essential role in the development of Dubin-Johnson syndrome.
Regev RH, Stolar O, Raz A, Dolfin T. Treatment of severe cholestasis in neonatal Dubin-Johnson syndrome with ursodeoxycholic acid. J Perinat Med. 2002. 30(2):185-7. [Medline].
Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore). 1954 Sep. 33(3):155-97. [Medline].
Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology. 1997 Jun. 25(6):1539-42. [Medline].
Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet. 1999 Mar. 64(3):739-46. [Medline]. [Full Text].
Kruh GD, Zeng H, Rea PA, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr. 2001 Dec. 33(6):493-501. [Medline].
Kimura A, Ushijima K, Kage M, et al. Neonatal Dubin-Johnson syndrome with severe cholestasis: effective phenobarbital therapy. Acta Paediatr Scand. 1991 Mar. 80(3):381-5. [Medline].
Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol. 2010 Oct. 24(5):555-71. [Medline].
Benz-de Bretagne I, Respaud R, Vourc'h P, et al. Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans. J Biomed Biotechnol. 2011. 2011:498757. [Medline]. [Full Text].
Nisa AU, Ahmad Z. Dubin-Johnson syndrome. J Coll Physicians Surg Pak. 2008 Mar. 18(3):188-9. [Medline].
van Kuijck MA, Kool M, Merkx GF, et al. Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet Cell Genet. 1997. 77(3-4):285-7. [Medline].
Frank M, Doss M, de Carvalho DG. Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome. Hepatogastroenterology. 1990 Feb. 37(1):147-51. [Medline].
Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol. 2006 Jun. 2(3):351-66. [Medline].
Hashimoto K, Uchiumi T, Konno T, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology. 2002 Nov. 36(5):1236-45. [Medline].
Tate G, Li M, Suzuki T, Mitsuya T. A new mutation of the ATP-binding cassette, sub-family C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Genes Genet Syst. 2002 Apr. 77(2):117-21. [Medline].
Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology. 2000 Dec. 32(6):1317-28. [Medline].
Uchiumi T, Tanamachi H, Kuchiwaki K, et al. Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin-Johnson syndrome. Hepatol Res. 2013 May. 43(5):569-75. [Medline].
Lee JH, Chen HL, Chen HL, Ni YH, Hsu HY, Chang MH. Neonatal Dubin-Johnson syndrome: long-term follow-up and MRP2 mutations study. Pediatr Res. 2006 Apr. 59(4 Pt 1):584-9. [Medline].
Zlotogora J. Hereditary disorders among Iranian Jews. Am J Med Genet. 1995 Jul 31. 58(1):32-7. [Medline].
Mor-Cohen R, Zivelin A, Fromovich-Amit Y, Kovalski V, Rosenberg N, Seligsohn U. Age estimates of ancestral mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian and Moroccan Jews are consistent with ancient Jewish migrations. Blood Coagul Fibrinolysis. 2007 Mar. 18(2):139-44. [Medline].
Liu C, Niu DM, Hsia CY, et al. Living donor liver transplantation using a graft from a donor with Dubin-Johnson syndrome. Pediatr Transplant. 2012 Feb. 16(1):E25-9. [Medline].
Korkmaz U, Duman AE, Ogutmen Koc D, et al. Severe jaundice due to coexistence of Dubin-Johnson syndrome and hereditary spherocytosis: a case report. Turk J Gastroenterol. 2011 Aug. 22(4):422-5. [Medline].
Fretzayas A, Kitsiou S, Papadopoulou A, Nicolaidou P. Clinical expression of co-inherited Dubin-Johnson and thalassaemic heterozygous states. Dig Liver Dis. 2007 Apr. 39(4):369-74. [Medline].
Mayatepek E, Lehmann WD. Defective hepatobiliary leukotriene elimination in patients with the Dubin-Johnson syndrome. Clin Chim Acta. 1996 May 30. 249(1-2):37-46. [Medline].
Respaud R, Benz-de Bretagne I, Blasco H, Hulot JS, Lechat P, Le Guellec C. Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of multidrug resistance protein 2 (MRP2) function in humans. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 15. 877(30):3893-8. [Medline].
Rocchi E, Balli F, Gibertini P, et al. Coproporphyrin excretion in healthy newborn babies. J Pediatr Gastroenterol Nutr. 1984 Jun. 3(3):402-7. [Medline].
Shimizu T, Tawa T, Maruyama T, Oguchi S, Yamashiro Y, Yabuta K. A case of infantile Dubin-Johnson syndrome with high CT attenuation in the liver. Pediatr Radiol. 1997 Apr. 27(4):345-7. [Medline].
Sobaniec-Lotowska ME, Lebensztejn DM. Ultrastructure of Kupffer cells and hepatocytes in the Dubin-Johnson syndrome: a case report. World J Gastroenterol. 2006 Feb 14. 12(6):987-9. [Medline].
Corpechot C, Ping C, Wendum D, Matsuda F, Barbu V, Poupon R. Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am J Gastroenterol. 2006 Oct. 101(10):2427-32. [Medline].